Intarcia Therapeutics, Inc. specializes in developing and systematically generating new uses for clinical-stage drugs licensed from major pharmaceutical companies. Intarcia also seeks to add value by redirecting development to new indications.
The strategy of redirected development is often the most efficient and cost effective means of advancing drugs rapidly into late stage development and into commercialization.
We also expand the utility of our products by developing new formulations, often in partnership with other companies, when such efforts will permit patients to be more comfortably or more effectively treated.
Since the founding of the company in 1997, Intarcia Therapeutics management has executed the strategies of redirected and expanded development, by forming partnerships with multiple international pharmaceutical companies, and has created a portfolio of products in advanced clinical testing in oncology and infectious diseases.